The present invention relates to a pharmaceutical combination comprising ranitidine hydrochloride and trimebutine maleate, wherein the combination of irritable bowel syndrome and convulsive colon accompanied by gastritis and reflux esophagitis in combination with four agents A new pharmaceutical combination that increases the convenience of the administration and economic efficiency by increasing the duration of treatment effect of gastritis and reflux esophagitis and the duration of treatment effect of irritable bowel syndrome and spastic colon In the treatment of irritable bowel syndrome and spastic colon associated with gastritis and reflux esophagitis, it is necessary to take two separate treatments, as well as the duration of treatment of gastritis and reflux esophagitis and the duration of irritable bowel syndrome and spastic colon Therapeutic effect duration is short Reobeon that will be taking one to solve the problem of the economic costs generated in accordance with the hassle and rising drug prices.That is, the present invention relates to a therapeutic agent for gastritis and reflux esophagitis, an irritable bowel syndrome, and a therapeutic agent for a seizure-prone colon, wherein the ranitidine hydrochloride immediate-release agent release includes a ranitidine hydrochloride immediate release formulation designed as a immediate release containing discrete ranitidine hydrochloride components for the primary treatment of gastritis and reflux esophagitis. Among the four types of preparations, which are composed of a combination of quadriceps and quadriceps, a ranitidine hydrochloride enteric coated release is disintegrated in the small intestine and is used to treat gastritis and reflux esophagitis secondary to ranitidine hydrochloride 0.0 > (ranitidine hydrochloride) Among the four preparations which consist of enteric coated release, ranitidine hydrochloride enteric coated release, and four treatments, one of which is trimerbutine maleate (trime
